Prof. Yifu He 何义富
Chief Physician, Professor
Department of Medical Oncology, Anhui Provincial Cancer Hospital, Hefei
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Diagnosis and treatment of gastrointestinal tumors, including esophageal, gastric, intestinal, liver, gallbladder, pancreatic cancers, and stromal tumors. Expertise in molecular targeted therapy, immunotherapy, psycho-oncology, and clinical research.
Dr. He holds a PhD in Oncology Pharmacology from Anhui Medical University and an MD from Sun Yat-sen University Cancer Center. Since 1997, Dr. He has worked in medical oncology at Anhui Provincial Hospital. Dr. He completed advanced studies in Florida, USA, in 2019. Dr. He serves as Principal Investigator for multiple clinical trials and contributed to the 2020 CSCO guidelines for esophageal and biliary tract malignancies.
Professional roles
- Vice Chair, Esophageal Cancer Professional Committee, Anhui Anti-Cancer Association
- Standing Committee Member, Gastric Cancer Expert Committee, Chinese Society of Clinical Oncology (CSCO)
- Standing Committee Member, Esophageal Cancer Expert Committee, Chinese Society of Clinical Oncology (CSCO)
- Chair, Gastrointestinal Tumor Professional Committee, Anhui Clinical Oncology Society
Name order: in Chinese the family name comes first (He Yifu). Papers usually list the name as Yifu He or He Y.
Selected publications
28 papers on PubMed matched by name and affiliation; 7 as first or senior author since 2016. Most recent first- or senior-author papers:
- BMC Cancer, 2026 (senior author): Surufatinib plus tislelizumab as later-line therapy for metastatic colorectal cancer: a single-arm, phase II trial. PubMed 41673617
- Oncology, 2026 (senior author): Patient-Reported Outcome-Based Symptom Management Improves Quality of Life in Postoperative Gastroesophageal Cancer Patients: A Randomized Controlled Trial. PubMed 40209689
- BMC Cancer, 2025 (senior author): Camrelizumab combined with apatinib plus irinotecan as a second-line treatment in advanced or metastatic esophageal squamous cell carcinoma patients. PubMed 40346506
- J Transl Med, 2025 (senior author): A humanized anti-MSLN×4-1BB bispecific antibody exhibits potent antitumour activity through 4-1BB signaling activation and fc function without systemic toxicity. PubMed 39806351
- BMC Cancer, 2024 (senior author): Association between quantitative CT body composition analysis and prognosis in cetuximab-based first-line treatment for advanced colorectal cancer patients. PubMed 39725871
- J Cancer Res Clin Oncol, 2023 (senior author): Pretreatment lymphocyte-monocyte ratio (LMR) as a superior predictor of short-term progression outcomes in patients with gastric cancer receiving second- and later-line apatinib regimens. PubMed 37308747
- Oncol Lett, 2020 (senior author): Limb-bud and heart as a novel biomarker for gastric intestinal type adenocarcinoma. PubMed 32782537
- Oncol Lett, 2015 (first author): Clinical features and prognosis-associated factors of non-small cell lung cancer exhibiting symptoms of bone metastasis at the time of diagnosis. PubMed 26137132
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion